NIKKEI 225
38,616.24 -330.69 (-0.85%) HANG SENG
19,298.01 +77.39 (+0.40%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,417.50 -8.40 (-0.35%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,971.55 -839.12 (-1.50%)
Journey Medical Corporation (DERM)
- GlobeNewswire
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the All
- GuruFocus.com
Journey Medical Corp (DERM) (Q1 2024) Earnings Call Transcript Highlights: Navigating Growth ...
Explore key financial outcomes, strategic moves, and future prospects as Journey Medical Corp reports a dynamic first quarter.
- GlobeNewswire
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., May 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” o
